. RAS does not confer sensitivity or resistance to CQ in DU145 cells. (A) DU145 cells or DU145 cells stably integrated with empty vector control or HRAS G12V were treated with chloroquine (30 µM) for increasing lengths of time and then cells were lysed and immunoblotted for LC3 and ACTB. (B, C, D) Parental DU145 cells or DU145 cells stably integrated with empty vector control or HRAS G12V were treated with CQ for 48 h and cell viability, cytotoxicity, and growth were measured by (B) MTS viability assay, (C) LDH release, and (D) clonogenic growth assay as measured by crystal violet staining 5 days after removing the CQ and adding growth media.
Figure S2
. RAS status or basal autophagy does not correlate with autophagy dependence in NSCLC lung cell lines. (A) H322C, HCC4006, and Calu3 (wt RAS, indicated by filled symbols) and H358, A549, and H2009 (oncogenic KRAS mutant, indicated by unfilled symbols) NSCLC cancer cell lines were treated with chloroquine and assayed by MTS viability assay at 48 h. (B) The RAS and TP53 mutation status of the 6 cell lines and their approximate CQ sensitivity are shown. # No mutations in TP53 have been described for HCC4006, but to our knowledge, wild-type status has not yet been verified. (C) H322C, HCC4006, Calu-3 and H358, A549, and H2009 NSCLC cancer cell lines were treated with CQ (30 µM) for the indicated timepoints and then cells were lysed and immunoblotted for SQSTM1, LC3, and ACTB (top panels). Similarly, for comparison, these cells were treated with or without CQ (30 µM) for 4 h and then cells were lysed and lysates on the same blot were immunoblotted for SQSTM1, LC3, and ACTB (bottom panels). (A) Matched HCT116 cells with or without somatic TP53 deletion were exposed CQ for 48 h, and cell viability was examined by MTS viability assay. (B) HCT116 cells were exposed to CQ for 48 h, and cell growth was examined by clonogenic growth assay as measured by crystal violet staining 5 days after removing the CQ and adding growth media. (C) HCT116 cells were treated with CQ for 48 h, and cell death was measured by LDH assay. (D) HCT116 cells were treated with CQ (30 µM) for the indicated timepoints and then cells were lysed and immunoblotted for LC3 and ACTB. (E) HCT116 cells were treated with doxorubicin for 48 h, and cell viability was examined by MTS viability assay were left untreated or were treated with or without doxycycline (100 ng/mL) for 1 or 3 days. In some cells bafilomycin A 1 (10 nM) was added for 4 h to block flux and then cells were lysed and immunoblotted for LC3 and ACTB to measure basal autophagy. (B) HOSE-HRAS G12V cells (400) were plated in a 6-well plate and left untreated or were treated with doxycycline (100 ng/mL) for 21 days and analyzed by crystal violet staining. (C and D) HOSE-HRAS G12V cells were treated with doxycycline (100 ng/mL) for 15 d and analyzed by PI exclusion using fluorescence microscopy. Sample picture is shown in (C), and quantification is shown in (D). (E) Similar to (B), 500 HOSE-HRAS G12V cells infected with lentivirus expressing ATG7 shRNA or a non-silencing control shRNA were plated on in a 6-well plate and left untreated or were treated with doxycycline (100ng/mL) for 16 days. Cells were fixed and analyzed by crystal violet staining. Quantification of the dye at 540 nm was done after dissolving in 33% acetic acid. (F) HOSE-HRAS G12V cells (uninduced) were infected with a KRAS G12V retrovirus or empty vector virus and, after selection, were exposed to various doses of CQ for 48 h, and cell death was measured by LDH assay. 
